



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/840,669	04/23/2001	Tadahiko Kohno	A-690

21069  
AMGEN INCORPORATED  
MAIL STOP 27-4-A  
ONE AMGEN CENTER DRIVE  
THOUSAND OAKS, CA 91320-1799



**CONFIRMATION NO. 4141**  
**FORMALITIES LETTER**



\*OC00000008177940\*

Date Mailed: 05/23/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



#9

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Tadahiko Kohno

Serial No.: 09/840,669

Filed: April 23, 2001

For: APO-AI/AII PEPTIDE DERIVATIVES

Docket No.: A-690

**ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: June 7, 2002

Please send all future correspondence to:  
U.S. Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling  
number:

EL360693885US

Date of  
Deposit:

June 7, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum  
Printed Name

  
Signature



06 - 10 - 02

0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Tadahiko Kohno

Serial No.: 09/840,669

Group Art Unit No.: 1614

Filed: April 23, 2001

Examiner:

For: APO-AI/AII PEPTIDE DERIVATIVES

Docket No.: A-690

TRANSMITTAL OF DECLARATION UNDER 37 CFR §1.821  
RESPONSE TO NOTICE TO COMPLY

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This is in response to a "Notice to Comply" dated May 23, 2002 noting the need for a correction in the sequence listing previously provided in the above-identified application.

Enclosed herewith are: 1) an Attorney's Statement pursuant to 37 CFR §1.821 and 2) a corrected Sequence Listing to be filed in this application.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: June 7, 2002

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling  
number:

EL360693885US

Date of  
Deposit:

June 7, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum  
Printed Name

Signature